Volume 9, Number 11—November 2003
Research
West Nile Virus Infection in Nonhuman Primate Breeding Colony, Concurrent with Human Epidemic, Southern Louisiana
Table 3
Animal no. | CF antibody titer |
|||||
---|---|---|---|---|---|---|
DENV-1 |
||||||
DENV-1 | DENV-2 | YFV | SLEV | WNV | PRNT antibody titer with WNV | |
CK62 | 0 | 0 | 0 | 16/8b | 128/>32 | 1:320c |
CL07 | 0 | 0 | 0 | 8/8 | 64/>32 | 1:160 |
CL11 | 0 | 0 | 0 | 8/8 | 64/>32 | 1:1280 |
CL80 | 0 | 0 | 0 | 16/8 | 128/>32 | 1:80 |
CL93 | 0 | 0 | 0 | 32/8 | 128/>32 | 1:320 |
CM11 | 0 | 0 | 0 | 0 | 16/>32 | 1:160 |
CP90 | 0 | 0 | 0 | 0 | 32/>32 | 1:160 |
CR36 | 0 | 0 | 0 | 8/8 | 64/>32 | 1:320 |
aViral antigens used in CF test: DENV, dengue virus; YFV, yellow fever virus; SLEV, St. Louis encephalitis virus; WNV, West Nile virus.
bCF titers expressed as reciprocal of highest antibody titer/reciprocal of antigen titer.
cPRN titers expressed as highest serum dilution producing >90% plaque reduction.
Page created: April 20, 2012
Page updated: April 20, 2012
Page reviewed: April 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.